Evidence map›Paper›PMID 38057927›Full record

Trial reportTrials2023

A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trial.

Robert K Mahar, Anna McGlothlin, Michael Dymock, Todd C Lee, Roger J Lewis, Thomas Lumley, Jocelyn Mora, David J Price, Benjamin R Saville, Tom Snelling and 6 more

Registry-linked trialAbstract readClinical TrialAdaptive Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05137119 (Staphylococcus Aureus Network Adaptive Platform Trial), which is not on this map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05137119 phase4recruitingnot on this map

Staphylococcus Aureus Network Adaptive Platform Trial

TypeinterventionalSponsorUniversity of MelbourneRan2022 to 2028Enrolled8,000ConditionsStaphylococcus Aureus BacteremiaArmsCefazolin, Penicillin, Clindamycin, Vancomycin, Effectiveness of early switch to oral antibiotics
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Cefazolin for Methicillin-SusceptibleThe New England journal of medicine · 2026
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Robert K Mahar *Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia. robert.mahar@unimelb.edu.au.ORCID http://orcid.org/0000-0002-3643-923X
Anna McGlothlin *Berry Consultants LLC, Austin, Texas, USA.
Michael DymockWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia.
Todd C LeeDivision of Infectious Diseases, Department of Medicine, McGill University, Montreal, Canada.
Roger J LewisBerry Consultants LLC, Austin, Texas, USA.
Thomas LumleyDepartment of Statistics, University of Auckland, Auckland, New Zealand.
Jocelyn MoraDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
David J PriceCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Parkville, Victoria, Australia.
Benjamin R SavilleBerry Consultants LLC, Austin, Texas, USA.
Tom SnellingWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia.
Rebecca TurnerMedical Research Council Clinical Trials Unit at University College London, London, United Kingdom.
Steven A WebbSt John of God Healthcare, Perth, Western Australia, Australia.
Joshua S DavisDepartment of Infectious Diseases, John Hunter Hospital, Newcastle, New South Wales, Australia.
Steven Y C TongDepartment of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Parkville, Victoria, Australia.
Julie A MarshWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, Western Australia, Australia.
SNAP Global Trial Steering Committee

Funding

CIHR 451092Medical Research Council MC_UU_00004/07Medical Research Council MC_UU_00004/09
6 · The paper itself

Abstract

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of S. aureus bloodstream infection. Here, we formalise the trial structure, modelling approach, and decision rules that will be used for the SNAP trial. By summarising the statistical principles governing the design, our hope is that the SNAP trial will serve as an adaptable template that can be used to improve comparative effectiveness research efficiency in other disease areas.Trial registration NCT05137119 . Registered on 30 November 2021.

Indexed as

SepsisStaphylococcal InfectionsAdultBayes TheoremChildHumansStaphylococcus aureusAdaptiveBayesianPlatformRandomisedStaphylococcus aureusTrial

Identifiers

PMID38057927
PMCPMC10699085

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.